IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation

Abali H., Oyan B., Koc Y., Kars A., Barista I., ÜNER A., ...Daha Fazla

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.28, sa.3, ss.264-269, 2005 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 3
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1097/01.coc.0000145984.39639.0d
  • Dergi Adı: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.264-269
  • Anahtar Kelimeler: lymphoma, salvage, transplantation, relapse, BONE-MARROW-TRANSPLANTATION, NON-HODGKINS-LYMPHOMA, HIGH-DOSE THERAPY, P-GLYCOPROTEIN, FOLLOW-UP, CHEMOTHERAPY, IFOSFAMIDE, RESISTANCE, DISEASE, EXPRESSION
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Patients with relapsed lymphoma can be cured with high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). New therapeutic approaches with better cytoreductive capacity are needed for relapsed patients to keep their chance for cure with transplantation. We report 30 patients with relapsed lymphoma, median age 43 years, treated with IIVP salvage regimen consisting of ifosfamide, mesna, idarubicin, and etoposide for 2 or 3 cycles. Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD). Four-teen (47%) patients were at their first relapse. Overall response rate was 86.6% (n = 26) with 19 patients (63.3%) achieving complete response. Overall response rate was 92% in patients with HD and 82% in NHL. The most frequent side effects observed were grade III-IV neutropenia (87%) and thrombocytopenia (73%). IIVP regimen is a highly effective salvage therapy for patients with relapsed HD or NHL who are candidates for autologous HSCT. Close follow up is necessary because of the high incidence of grade III-IV hematologic toxicity.